Menu
© 2019 All rights reserved.
YBhg. Dato’ Sri Mohd Mokhtar was appointed to the Board on 25 January 2019.
YBhg. Dato’ Sri Mohd Mokhtar holds a degree in Bachelor of Law (Hons), a Masters of Business Administration and a Certificate of Legal Practice
YBhg. Dato’ Sri Mohd Mokhtar had served the Royal Malaysia Police 3rd July 1977 – 22nd May 2018. Positions held during his service were as follows:
Aged 35, Malaysian
Executive Director
Group Chief Executive Officer
Ms. Nadiah Wan, aged 34, was appointed as Chief Executive Officer of Thomson Hospitals Sdn Bhd and Group Chief Corporate Officer of TMC Life Sciences Berhad on 19 June 2017.
Prior to joining Thomson Hospitals Sdn Bhd and the Company, Ms. Nadiah Wan worked in Sunway Medical Centre as Chief Operating Officer (Clinical Services) after being promoted from Director of Business Development and Corporate Communications in October 2016. She started her career at The Boston Consulting Group in 2007 as an Associate Consultant before joining Sunway Group as Manager, Strategy and Corporate Development in 2010.
Ms. Nadiah Wan holds MSc Public Health Nutrition degree qualification from the London School of Hygiene and Tropical Medicine, UK and an AB cum Laude in Biochemical Sciences from Harvard College. She also serves as an Interviewer for Harvard College admissions and is an Exco member of the Harvard Club of Malaysia.
Ms. Nadiah Wan does not hold any directorship in other public companies and listed issuer in Malaysia. She has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, she has no conflict of interest with the Company.
Aged 64, Malaysian
Executive Director
Member of Nomination Committee
Mr. Barry Kan was appointed to the Board on 2 June 2015. He is a veteran of almost 30 years in the automotive industry with rich and vast experience in managing various illustrious global brands during his career with renowned regional dealership, Wearnes Automotive, headquartered in Singapore. Prior to that, he was with the Port Authority of Singapore for 7 years.
As General Manager at Malayan Motors (a division then of Wearnes Automotive Pte Ltd), his portfolio included the Rolls-Royce, Bentley, Jaguar and Volvo Trucks franchises in Singapore. He was also responsible for the introduction of some of the brands into new territories such as Brunei, Indonesia, Taiwan and Thailand. In addition to the strategic management of the business, he took personal interest in Customer Relationship Management and Aftersales operations, which resulted in a high level of clientele retention for the luxury automotive brands.
Promoted to Managing Director of the Prestige Division of Wearnes Automotive, he was instrumental in the acquisition of new brands which included Bugatti, Land Rover and McLaren. He was also the key representative of the company for the high-society clientele which included the Captains of Industry as well as esteemed members of Royal families within the region.
To nurture the passion for driving and motorsports for the entire Corporate Group, he led a team to spearhead the inaugural motorsports division. Activities included track and instructional driving days as well as distance driving weekends in Malaysia where participants had the chance to learn more about their cars and improve their driving skills whilst the company had the chance to showcase their product range and services.
When the exciting opportunity arose to develop the integrated automotive hub in Nusajaya, Iskandar Malaysia, he joined Fastrack Autosports (Iskandar) Pte Ltd to conceptualise and execute the project, in partnership with UEW Sunrise Berhad. Mr. Kan leads the joint venture company, Fastrack Iskandar Sdn Bhd as its Chief Executive Officer.
Mr. Kan has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Mr. Gary Ho Kuat Foong was appointed to the Board of TMC Life Sciences Berhad on 12 January 2011.
Mr. Ho has over 36 years’ experience in corporate management and finance. He currently sits on the Board of several private and public listed companies in Australia and Singapore respectively.
Mr. Ho holds Bachelor degrees in Commerce and Science from the University of Western Australia. He is a member of CPA Australia and the Institute of Singapore Chartered Accountants.
Mr. Ho has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Ms. Claire Lee Suk Leng was appointed to the Board on 18 October 2012.
Ms. Claire Lee holds Bachelor of Business Administration (Distinction) in Finance from the University of Hawaii at Manoa. Ms. Claire Lee has over 10 years of experience in the areas of corporate finance and advisory, and private wealth management. She started her career with the merchant banking arm of the Union Bank of Switzerland, UBS (East Asia) Ltd and later joined HSBC Investment Bank plc and Salomon Smith Barney (Singapore) Pte Ltd.
Ms. Claire Lee has no family relationship with any Director and/or major shareholder of the Company. She has no conviction of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. She has no conflict of interest with the Company. She does not hold any directorship in other public companies and listed issuers in Malaysia.
Dr. George Lam was appointed to the Board on 25 January 2019.
Dr. Lam holds a BSc in sciences and mathematics, an MSc in systems science and an MBA from the University of Ottawa in Canada, a post-graduate diploma in public administration from Carleton University in Canada, a post-graduate diploma in English and Hong Kong Law and an LLB (Hons) in law from Manchester Metropolitan University in the UK, a LLM in law from the University of Wolverhampton in the UK, a PCLL in law from the City University of Hong Kong, a Certificate in Professional Accountancy from the Chinese University of Hong Kong SCS, an MPA and a PhD from the University of Hong Kong. A former member of the Hong Kong Bar, Dr. Lam is a Solicitor of the High Court of Hong Kong, an Honorary Fellow of CPA Australia, a Fellow of CMA Australia and the Hong Kong Institute of Arbitrators, an Accredited Mediator of the Centre for Effective Dispute Resolution (CEDR), a Fellow of the Hong Kong Institute of Directors, and an Honorary Fellow of the Hong Kong Institute of Facility Management and the University of Hong Kong School of Professional and Continuing Education (HKU SPACE).
Dr. Lam has over 30 years of international experience in general management, management consulting, corporate governance, direct investment, investment banking and fund management across the telecommunications/media/technology (TMT), consumer/healthcare, infrastructure/real estates, energy/resources and financial services sectors.
Dr. Lam is Chairman of Hong Kong Cyberport Management Company Limited, Non-Executive Chairman – Hong Kong and ASEAN Region and Chief Adviser to Macquarie Infrastructure and Real Assets Asia, a member of the Hong Kong Special Administrative Region Government’s Committee on Innovation, Technology and Re-Industrialization, and the Court of the City University of Hong Kong, Convenor of the Panel of Advisors on Building Management Disputes of the Hong Kong Special Administrative Region Government Home Affairs Department, President of the United Nations Economic and Social Commission for Asia and the Pacific (UN ESCAP) Sustainable Business Network (ESBN) Executive Council and Chairman of its Task Force on Banking and Finance, a Board member of Pacific Basin Economic Council (PBEC), a member of the Hong Kong Trade Development Council Belt and Road Committee and the Sir Murray MacLehose Trust Fund Investment Advisory Committee, Honorary Advisor to the Hong Kong Business Angel Network (HKBAN), and Honorary Chairman – Asia Pacific of CMA Australia.
Dr. Lam has no family relationship with any Director and/or major shareholder of the Company. He has no conviction of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 51, Malaysian
Independent Non-Executive Director
Mr. Cheah Ho Chee was appointed to the Board on 1 July 2022. He is currently the Chief Executive Officer of a boutique developer and real estate advisory firm known as ARX International where he draws on his expertise across the full property spectrum to advice on Property Development and Project Management. He is also the Chairman of SCM, an ISO 9001 accredited and Tier 1 Asset and Property Management firm.
Mr. Cheah has amassed over 25 years of professional experience across multiple countries. He has developed and managed projects in excess of RM60 billion comprising multiple Successful and Award-Winning Mixed-Use Developments, Residences, Commercial, Education Campus and Industrial developments in Malaysia and spanning across Australia, Singapore, Canada and South Africa. He also successfully managed the property development joint venture in Singapore between the sovereign wealth funds of Malaysia and Singapore.
Mr. Cheah was the Chief Operating Officer of UEM Sunrise and spearheaded the Local and International Portfolios. He was later headhunted to lead Mah Sing’s overseas expansion as Chief Executive Officer, International. Thereafter, he took the helm as the Chief Executive Officer of MRCB Land to oversee both Local and International portfolios.
Mr. Cheah holds an MBA with Distinction from the University of Sunderland in United Kingdom and BSc (Hons) Civil and Structural Engineering from the University of Iowa City in United States. He also attended Harvard Business School, ASEAN Senior Management Program.
Mr. Cheah has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 48, Malaysian
Independent Non-Executive Director
Ms. June Leong Lai Ling was appointed to the Board on 1 July 2022. She holds a Masters in Business Administration from Peking University in Beijing and BSc in Engineering with Management from King’s College London in United Kingdom.
Ms. June Leong currently serves as Independent Director of Thomson Medical Group Limited (“TMGL”) and is a member of the Audit and Risk Committee of TMGL. She is also currently the Chief Executive Officer of Alpha Goal International (“Alpha Goal”), a dedicated single-family office making investments around the world in a variety of asset classes including a portfolio of listed equities, hedge funds, and private equity funds.
Prior to joining Alpha Goal, Ms. June Leong was the Executive Director for China International Capital Corporation. She started her career as an Analyst with Morgan Stanley’s investment banking division in Singapore in 1995. Subsequently, she was appointed as an Executive Director of Goldman Sachs Private Wealth Management based in Hong Kong, covering Hong Kong, China and Southeast Asian clients from February 2006 to October 2008.
Ms. June Leong has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year under review. She has no conflict of interest with the Company. She does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 71, Malaysian
Non-Independent Non-Executive Chairman
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was appointed to the Board on 7 October 2004. He graduated with first-class honours in B.Med. Sc. (1973) and a first class honours in MBBS from Monash University, Australia in 1975 and PhD in 1982. He was awarded the FRACP (Australia) and FRCP’s from Edinburgh, Glasgow, Ireland and London and the Honorary Fellowship of the American College of Physician in June 2008 and is a Fellow of the Academy of Science Malaysia.
Professor Emeritus Dato’ Dr. Khalid started his career as a lecturer at Universiti Kebangsaan Malaysia (“UKM”) in 1982, promoted to Associate Professor in 1984, Head of Department of Medicine in 1985, Dean of the Medical Faculty and Professor in 1990. In 1997-2000, he was Director of the new Hospital Universiti Kebangsaan Malaysia (“HUKM”) with the task of building up HUKM. Upon his retirement in 2004, he was awarded the title of Professor Emeritus.
He then joined Monash University as Professor of Medicine and started the Tan Sri Jeffery Cheah Clinical School in Johor.
He was one of the pioneers of the Company and Thomson Hospitals (formerly known as Tropicana Medical Centre) and is currently the consultant Endocrinologist.
He was in the Malaysia Medical Council from 1986 to 2001, President of the Persatuan Diabetes Malaysia from 1985 to 1990, President of the Malaysia Endocrine Society from 1995 to 2001, Member of Council, International Diabetes Federation from 2001 to 2002, and Master of The Academy of Medicine of Malaysia from 2006 to 2008.
He is active in research and has published more than 310 papers in international and national peer reviewed journals. Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was conferred The National Science Award in 1997, The Asia Pacific Nutrition Award in 1996 and The Merdeka Award in 2008, and delivered The Tunku Abdul Rahman Oration, Academy Medicine Malaysia 2010, and the Gold Medal for outstanding services to Malaysian Medical Association May 2016.
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.